Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...

Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Semaglutide — the key ingredient in Ozempic and Wegovy — had been in shortage since 2022. Now that supply has stabilized, state-licensed compounding pharmacies and physicians must stop selling ...

Mumbai: Pharma major, Sun Pharmaceutical, is gearing up to introduce its experimental anti-obesity and type 2 diabetes ...

A generic drug is an exact copy of the active ... for certain conditions is prescribed for another purpose.) Wegovy, a drug that is FDA approved for weight loss, has the same active ingredient ...

David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous value they offer.

"The reality in the market is (Wegovy) remains in short supply ... and said it expected to keep offering "personalized" compounded drugs and generic versions of an older Novo Nordisk medicine.

Feb 21 (Reuters) - The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's NOVOb.CO popular weight-loss and diabetes drugs, Wegovy and ...